Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …

The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use
from the recurrence setting to the frontline setting. In parallel, the population developing …

Purpose: PARP inhibitors are approved for the treatment of high-grade serous ovarian
cancers (HGSOC). Therapeutic resistance, resulting from restoration of homologous …

Ovarian cancer (OC) constitutes the most common cause of gynecologic cancer-related
death in women worldwide. Despite consistent developments in treatment strategies for OC …

PARP inhibitors (PARPIs) have revolutionized the treatment of epithelial ovarian cancer, first
for BRCA-associated cancer, and, recently, for all epithelial cancers of serous or high-grade …

Poly (ADP-ribose) polymerase (PARP) enzymes have been shown to be essential for DNA
repair pathways, including homologous recombination repair (HRR). Cancers with HRR …

Patients with cancer treated with PARP inhibitors (PARPi) experience various side effects,
with hematologic toxicity being most common. Short-term treatment of mice with olaparib …

Olaparib is a poly (ADP-ribose) polymerase inhibitor (PARPi) that inhibits PARP1/2, leading
to replication-induced DNA damage that requires homologous recombination repair …

Background This study assessed the checkpoint kinase 1 inhibitor prexasertib in patients
with extensive-stage small-cell lung cancer (ED-SCLC). Patients and Methods This was a …

Introduction Patients with high-grade serous ovarian cancer (HGSOC) have a poor
prognosis, and current chemotherapy regimens for treating advanced disease are far from …